Unique ID issued by UMIN | UMIN000015750 |
---|---|
Receipt number | R000018295 |
Scientific Title | A Clinical Study for Evaluating the Safety of Excessive Consumption of Food Containing Pueraria Flower Extract -A Randomized, Double-blind, Placebo-controlled, Parallel-group Study- |
Date of disclosure of the study information | 2014/11/26 |
Last modified on | 2021/02/18 13:54:39 |
A Clinical Study for Evaluating the Safety of Excessive Consumption of Food Containing Pueraria Flower Extract
-A Randomized, Double-blind, Placebo-controlled, Parallel-group Study-
A Clinical Study for Evaluating the Safety of Excessive Consumption of Food Containing Pueraria Flower Extract
A Clinical Study for Evaluating the Safety of Excessive Consumption of Food Containing Pueraria Flower Extract
-A Randomized, Double-blind, Placebo-controlled, Parallel-group Study-
A Clinical Study for Evaluating the Safety of Excessive Consumption of Food Containing Pueraria Flower Extract
Japan |
No(Subjects under 30 of BMI)
Adult |
Others
NO
To evaluate the safety of excessive consumption of food containing pueraria flower extract for 4 weeks
Safety
Biochemical examination, Hematological examination, urine analysis, vital signs
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Food |
Food containing pueraria flower extract, 5-fold quantity of recommended daily intake
Food not containing pueraria flower extract
20 | years-old | <= |
65 | years-old | > |
Male and Female
(1)(Healthy) males and females aged 20 to 64 years old.
(2)Subjects under 30 of BMI.
(3)Subjects who can stop drinking from 2 days before each measurement.
(4)Subjects who can make self-judgment and are voluntarily giving written informed consent.
(1)Subjects who use medications affecting obesity, hyperlipidemia, lipid metabolism, and so on.
(2)Subjects who can't stop using supplements and/or fuctional foods affecting obesity, hyperlipidemia, lipid metabolism, and so on.
(3)Subjects who contract serious diabetes, kidney disease, liver disease, and/or disease needing immediate treatment.
(4)Subjects who have a history of digestive disease affecting digestion and absorption, and related surgery.
(5)Subjects who are under treatment for or have a history of drug addiction and/or alcoholism.
(6)Subjects who have been diagnosed as familial hyperlipidemia.
(7)Subjects who are planning to become pregnant after informed consent for the current study or are pregnant or lactating.
(8)Subjects who have donated blood compornents and/or blood a volume of 200 mL and over within one month prior to the current study.
(9)Subjects who are planning to participate or already participating in other clinical studies.
(10)Subjects who are judged as unsuitable for the study by the investigator for other reasons.
30
1st name | Haruhi |
Middle name | |
Last name | Sugimura |
C'est la vie Shimbashi Clinic
Medical office
105-0003
2-39-3 Nishishimbashi, Minato-ku, Tokyo
03-5408-8181
h-sugimura@shinkokai.jp
1st name | Yoshika |
Middle name | |
Last name | Komori |
KSO Corporation
Sales department
105-0023
1-9-7 Shibaura, Minato-ku, Tokyo
03-3452-7733
yoshi@kso.co.jp
KSO Corporation
TOYO SHINYAKU Co.,Ltd
Profit organization
Ethical Committee of C'est la vie Shimbashi Clinic
2-39-3 Nishishimbashi,Minato-ku, Tokyo
03-5408-8671
m-fujii@shinkokai.jp
NO
2014 | Year | 11 | Month | 26 | Day |
Unpublished
Completed
2014 | Year | 11 | Month | 17 | Day |
2014 | Year | 11 | Month | 27 | Day |
2014 | Year | 11 | Month | 27 | Day |
2015 | Year | 12 | Month | 31 | Day |
2014 | Year | 11 | Month | 25 | Day |
2021 | Year | 02 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018295